Navigation Links
Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
Date:3/21/2011

they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
2. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
3. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
4. Reportlinker Adds Shire plc: PharmaVitae Profile
5. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
6. Shire plc - Statement re ProAmatine
7. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
8. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
9. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
10. Shire plc Appoints Two New Board Directors
11. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014 Proove Biosciences , ... industry leading research and data on the association between ... American Academy of Pain Management’ s 25th ... Arizona at the , Proove Biosciences ... and genetic predisposition to opioid misuse risk in chronic ...
(Date:9/23/2014)... 2014 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... pleased to announce that its wholly owned subsidiary, ... consultants to its team for further development of ... proprietary cell permeable peptide platform technology derived from ... the eye. Ms. Holly ...
(Date:9/23/2014)... Austin, TX (PRWEB) September 23, 2014 ... newest fertility clinic in South Austin, expanding a Central ... Austin and San Antonio. The satellite office for the ... and andrology options to the South Austin, Buda, Kyle ... bring effective and affordable fertility treatment directly to individuals ...
(Date:9/23/2014)... 2014 New spin-out from ... Cambridge Innovation Capital and Johnson & Johnson Development ... company focused on harnessing the potential of circulating ... and treatment, today announced it has raised £4m ... and including Cambridge Innovation Capital and Johnson & ...
Breaking Biology Technology:Proove Biosciences Will Be Exhibiting I.M.P.L.O.R.E Study at the American Academy of Pain Management 25th Annual Meeting 2Proove Biosciences Will Be Exhibiting I.M.P.L.O.R.E Study at the American Academy of Pain Management 25th Annual Meeting 3Portage Announces New Consultants for its PPL-003 Development Programs 2Portage Announces New Consultants for its PPL-003 Development Programs 3Portage Announces New Consultants for its PPL-003 Development Programs 4Opening Doors to a Family: Texas Fertility Center Announces Newest Fertility Clinic in South Austin 2Opening Doors to a Family: Texas Fertility Center Announces Newest Fertility Clinic in South Austin 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4
... Zemea® propanediol, has been independently evaluated by NSF International and now ... Protection Agency (EPA) Design for the Environment (DfE) screen. Zemea® ... Products joint venture. , ... Loudon, TN (Vocus) December ...
... MISSISSAUGA, ON, Jan. 5 /PRNewswire-FirstCall/ - YM ... an oncology company that identifies, develops and ... announced that it has received clearance from ... II, double-blind, randomized trials for nimotuzumab, its ...
... Sangamo BioSciences,Inc. (Nasdaq: SGMO ) announced today ... update on the progress of Sangamo,s ZFP Therapeutic,development programs ... pm (PT) on Monday, January 12, 2009 at the ... The presentation will be webcast live and ...
Cached Biology Technology:Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria 2Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria 3YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 2YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 3YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 4YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 5YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 6YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 7Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference 2
(Date:9/23/2014)... Ill. Scientists have scoured cow rumens and termite ... cell walls for the production of next-generation biofuels, but ... in the human lower intestine, researchers report. , Their ... the National Academy of Sciences , is the first ... microbes in the human gut can digest fiber, breaking ...
(Date:9/23/2014)... majority of drugs used to treat asthma today are the ... are urgently needed to treat this chronic respiratory disease, which ... to wheeze, cough, and find it difficult at best to ... is tough: asthma is a patient-specific disease, so what works ... animal models traditionally used to test new drug candidates often ...
(Date:9/23/2014)... SPRINGS, Florida , September 23, 2014 ... for innovative companies in tech sector position for significant investor ... products & services.  Companies in focus today are: NXT-ID, Inc. ... BABA ), Mobileye N.V. (NYSE: MBLY ... Robotics Ltd. (NASDAQ: RWLK) NXT-ID, Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Search for better biofuels microbes leads to the human gut 2Search for better biofuels microbes leads to the human gut 3Airway muscle-on-a-chip mimics asthma 2Airway muscle-on-a-chip mimics asthma 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 2Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 4Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 5Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 6Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 7
... requires the same protein molecule that neurons need to ... to new research from the University of Illinois at ... the online journal PLOS ONE . , The ... cells into neurons and the process whereby cancer cells ...
... -- Critical to the recovery efforts following the devastating effects ... ability to assess damage within the reactor,s core. A study ... of scientists from Los Alamos National Laboratory (LANL) shows that ... to the reactor cores and locating the melted fuel. ...
... beverages containing toxins believed to pose potential risks to developing ... in Riverside and San Diego, suggesting that health care providers ... of hidden toxins in the food supply. In a ... Journal "Consumption habits of pregnant women and implications ...
Cached Biology News:Protein involved in nerve-cell migration implicated in spread of brain cancer 2Getting to the core of Fukushima 2Diets of pregnant women contain harmful, hidden toxins 2Diets of pregnant women contain harmful, hidden toxins 3Diets of pregnant women contain harmful, hidden toxins 4
Request Info...
Size & Applications: 100 ul (2 mM). Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.) Storage Temp.: -20C Shelf Life: 6-12 month...
in vitro Translation, Accessory Products...
... Origami host strains are K-12 derivatives ... reductase (trxB) and glutathione reductase (gor) genes, ... the cytoplasm. Studies have shown that expression ... than in another host even though overall ...
Biology Products: